Trial Profile
An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 Dec 2021
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications HIV-1 infections
- Focus Expanded access; Therapeutic Use
- Acronyms CD02_EA
- Sponsors CytoDyn
- 09 Dec 2021 According to a CytoDyn media release, company has filed a request with the U.S. Food and Drug Administration (FDA) for approval of expanded access use of leronlimab for multi-drug resistance (MDR) HIV patients.
- 09 Sep 2019 According to a CytoDyn media relerase, this trial is under the supervision of Jacob Lalezari, M.D.
- 30 Aug 2017 Status changed from suspended to completed.